- Home
- ABUS vs LENZ Comparison
ABUS vs LENZ Comparison
Compare ABUS & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- LENZ
- Stock Information
- Founded
- ABUS N/A
- LENZ 2019
- Country
- ABUS United States
- LENZ United States
- Employees
- ABUS N/A
- LENZ N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- LENZ Medicinal Chemicals and Botanical Products
- Sector
- ABUS Health Care
- LENZ Health Care
- Exchange
- ABUS Nasdaq
- LENZ Nasdaq
- Market Cap
- ABUS 617.3M
- LENZ 729.6M
- IPO Year
- ABUS N/A
- LENZ 2021
- Fundamental
- Price
- ABUS $3.51
- LENZ $25.51
- Analyst Decision
- ABUS Strong Buy
- LENZ Strong Buy
- Analyst Count
- ABUS 4
- LENZ 6
- Target Price
- ABUS $5.50
- LENZ $38.00
- AVG Volume (30 Days)
- ABUS 1.0M
- LENZ 249.6K
- Earning Date
- ABUS 03-27-2025
- LENZ 03-19-2025
- Dividend Yield
- ABUS N/A
- LENZ N/A
- EPS Growth
- ABUS N/A
- LENZ N/A
- EPS
- ABUS N/A
- LENZ N/A
- Revenue
- ABUS $6,171,000.00
- LENZ N/A
- Revenue This Year
- ABUS N/A
- LENZ N/A
- Revenue Next Year
- ABUS $61.99
- LENZ $535.40
- P/E Ratio
- ABUS N/A
- LENZ N/A
- Revenue Growth
- ABUS N/A
- LENZ N/A
- 52 Week Low
- ABUS $2.30
- LENZ $14.42
- 52 Week High
- ABUS $4.72
- LENZ $38.93
- Technical
- Relative Strength Index (RSI)
- ABUS 58.89
- LENZ 52.69
- Support Level
- ABUS $3.20
- LENZ $24.10
- Resistance Level
- ABUS $3.45
- LENZ $27.89
- Average True Range (ATR)
- ABUS 0.14
- LENZ 1.82
- MACD
- ABUS 0.03
- LENZ 0.07
- Stochastic Oscillator
- ABUS 78.65
- LENZ 45.54
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.